UNASSIGNED: In non-osteoporotic postmenopausal @entity1 with @entity0 , aromatase inhibitors (AIs) negatively affected @entity79 ( @entity79 ), lumbar spine @entity79 ( @entity79 ) as a bone microarchitecture index, and hip geometry as a bone macroarchitecture index. INTRODUCTION: AIs increase the risk of @entity174 in @entity1 with @entity0 . Therefore, we aimed to evaluate the long-term skeletal effects of AIs in postmenopausal @entity1 with primary @entity0 . METHODS: We performed a retrospective longitudinal observational study in non-osteoporotic @entity1 with @entity0 who were treated with AIs for >= 3  years (T-score >-2.5). @entity1 with previous anti- @entity170 treatment or those who were given @entity5520 during AI treatment were excluded from the analysis. We serially assessed @entity79 , lumbar spine @entity79 , and hip geometry using dual-energy X- @entity16039 absorptiometry. RESULTS: @entity79 significantly decreased from baseline to 5  years at the lumbar spine (-6.15%), femur neck (-7.12%), and total hip (-6.35%). Lumbar spine @entity79 also significantly decreased from baseline to 5  years (-2.12%); this change remained significant after adjusting for lumbar spine @entity79 . The annual loss of lumbar spine @entity79 and @entity79 slowed after 3 and 1  year of treatment, respectively, although there was a relatively constant loss of @entity79 at the femur neck and total hip for up to 4  years. The cross-sectional area, cross-sectional moment of inertia, minimal neck width, femur strength index, and section modulus significantly decreased, although the buckling ratio increased over the treatment period (all P  <  0.001); these changes were independent of total hip @entity79 . CONCLUSIONS: Long-term adjuvant AI treatment negatively influenced bone quality in addition to @entity79 in @entity1 with @entity0 . This study suggests that early monitoring and management are needed in non-osteoporotic @entity1 with @entity0 who are starting AIs.

Long-term effect of aromatase inhibitors on bone microarchitecture and macroarchitecture in non-osteoporotic postmenopausal @entity1 with XXXX .

@entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer'] @entity174 :: ('MESH:D050723', 'Disease') :: ['fracture'] @entity16039 :: ('255564', 'Species') :: ['ray'] @entity170 :: ('MESH:D010024', 'Disease') :: ['osteoporosis'] @entity79 :: ('MESH:D001847', 'Disease') :: ['bone mineral density', 'BMD', 'trabecular bone score', 'TBS'] @entity5520 :: ('D004164', 'Chemical') :: ['bisphosphonate']
@entity0 :: (MESH:D001943,Disease) :: ['breast cancer']
